CADTH Issues Draft Recommendation for Trikafta for 2-5 Year olds
OCTOBER 27, 2023
Canadian children are one step closer to accessing Trikafta as the Canadian Agency for Drugs and Technologies in Health (CADTH) has released its draft recommendation to fund the treatment for kids aged two and older with the most common CF mutation.
What is next?
We are pleased with the direction of the draft recommendation but will be reviewing it in detail and will consult with our Healthcare Advisory Council, clinical trials network and other CF clinicians and provide feedback to CADTH on the draft recommendation.
The feedback period will end on November 9, we expect a final recommendation to come before the end of Nov.
Following the final recommendation, provinces and territories will make decisions on whether or not to include 2–5-year-olds in their funding of the drug. Cystic Fibrosis Canada is calling on the public and private payers to list Trikafta for all who could benefit, immediately.
Stay tuned to our channels for more updates as they become available. #TrikaftaForAll